Asia-Pacific Chronic Idiopathic Constipation (CIC) Drugs Market Report 2018

Table of Contents

1 Report Overview

• 1.1 Definition and Specification
• 1.2 Report Overview
  • 1.2.1 Manufacturers Overview
  • 1.2.2 Regions Overview
  • 1.2.3 Type Overview
  • 1.2.4 Application Overview
• 1.3 Industrial Chain
  • 1.3.1 Chronic Idiopathic Constipation (CIC) Drugs Overall Industrial Chain
  • 1.3.2 Upstream
  • 1.3.3 Downstream
• 1.4 Industry Situation
  • 1.4.1 Industrial Policy
  • 1.4.2 Product Preference
  • 1.4.3 Economic/Political Environment
• 1.5 SWOT Analysis

2 Market Analysis by Types

• 2.1 Overall Market Performance(Volume)
  • 2.1.1 Lubiprostone Market Performance (Volume)
  • 2.1.2 Linaclotide Market Performance (Volume)
  • 2.1.3 Others Market Performance (Volume)
• 2.2 Overall Market Performance(Value)
  • 2.1.1 Lubiprostone Market Performance (Value)
  • 2.1.2 Linaclotide Market Performance (Value)
  • 2.1.3 Others Market Performance (Value)

3 Product Application Market

• 3.1 Overall Market Performance (Volume)
  • 3.1.1 Hospitals & Clinics Market Performance (Volume)
  • 3.1.2 Ambulatory Surgical Centres Market Performance (Volume)
  • 3.1.3 Long Term Care Centres Market Performance (Volume)
  • 3.1.4 Others Market Performance (Volume)

4 Manufacturers Profiles/Analysis

• 4.1 Actavis
  • 4.1.1 Actavis Profiles
  • 4.1.2 Actavis Product Information
  • 4.1.3 Actavis Chronic Idiopathic Constipation (CIC) Drugs Business Performance
  • 4.1.4 Actavis Chronic Idiopathic Constipation (CIC) Drugs Business Development and Market Status
• 4.2 Chugai Pharmaceutical
  • 4.2.1 Chugai Pharmaceutical Profiles
  • 4.2.2 Chugai Pharmaceutical Product Information
  • 4.2.3 Chugai Pharmaceutical Chronic Idiopathic Constipation (CIC) Drugs Business Performance
  • 4.2.4 Chugai Pharmaceutical Chronic Idiopathic Constipation (CIC) Drugs Business Development and Market Status
• 4.3 Ferring International Center S.A.
  • 4.3.1 Ferring International Center S.A. Profiles
  • 4.3.2 Ferring International Center S.A. Product Information
  • 4.3.3 Ferring International Center S.A. Chronic Idiopathic Constipation (CIC) Drugs Business Performance
  • 4.3.4 Ferring International Center S.A. Chronic Idiopathic Constipation (CIC) Drugs Business Development and Market Status
• 4.4 Synergy Pharmaceuticals
  • 4.4.1 Synergy Pharmaceuticals Profiles
  • 4.4.2 Synergy Pharmaceuticals Product Information
  • 4.4.3 Synergy Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Business Performance
  • 4.4.4 Synergy Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Business Development and Market Status
• 4.5 Pfizer
  • 4.5.1 Pfizer Profiles
  • 4.5.2 Pfizer Product Information
  • 4.5.3 Pfizer Chronic Idiopathic Constipation (CIC) Drugs Business Performance
  • 4.5.4 Pfizer Chronic Idiopathic Constipation (CIC) Drugs Business Development and Market Status
• 4.6 GlaxoSmithKline
  • 4.6.1 GlaxoSmithKline Profiles
  • 4.6.2 GlaxoSmithKline Product Information
  • 4.6.3 GlaxoSmithKline Chronic Idiopathic Constipation (CIC) Drugs Business Performance
  • 4.6.4 GlaxoSmithKline Chronic Idiopathic Constipation (CIC) Drugs Business Development and Market Status
• 4.7 Roche Holding AG
  • 4.7.1 Roche Holding AG Profiles
  • 4.7.2 Roche Holding AG Product Information
  • 4.7.3 Roche Holding AG Chronic Idiopathic Constipation (CIC) Drugs Business Performance
  • 4.7.4 Roche Holding AG Chronic Idiopathic Constipation (CIC) Drugs Business Development and Market Status
• 4.8 Sanofi
  • 4.8.1 Sanofi Profiles
  • 4.8.2 Sanofi Product Information
  • 4.8.3 Sanofi Chronic Idiopathic Constipation (CIC) Drugs Business Performance
  • 4.8.4 Sanofi Chronic Idiopathic Constipation (CIC) Drugs Business Development and Market Status
• 4.9 Bayer AG
  • 4.9.1 Bayer AG Profiles
  • 4.9.2 Bayer AG Product Information
  • 4.9.3 Bayer AG Chronic Idiopathic Constipation (CIC) Drugs Business Performance
  • 4.9.4 Bayer AG Chronic Idiopathic Constipation (CIC) Drugs Business Development and Market Status
• 4.10 Salix Pharmaceuticals Ltd
  • 4.10.1 Salix Pharmaceuticals Ltd Profiles
  • 4.10.2 Salix Pharmaceuticals Ltd Product Information
  • 4.10.3 Salix Pharmaceuticals Ltd Chronic Idiopathic Constipation (CIC) Drugs Business Performance
  • 4.10.4 Salix Pharmaceuticals Ltd Chronic Idiopathic Constipation (CIC) Drugs Business Development and Market Status
• 4.11 Sucampo Pharmaceuticals Inc
• 4.12 Ironwood Pharmaceuticals
• 4.13 Ferring International Center S.A.

5 Market Performance for Manufacturers

• 5.1 Asia-Pacific Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units) and Market Share by Manufacturers 2013-2018
• 5.2 Asia-Pacific Chronic Idiopathic Constipation (CIC) Drugs Revenue (M USD) and Market Share by Manufacturers 2013-2018
• 5.3 Asia-Pacific Chronic Idiopathic Constipation (CIC) Drugs Price (USD/Unit) of Manufacturers 2013-2018
• 5.4 Asia-Pacific Chronic Idiopathic Constipation (CIC) Drugs Gross Margin of Manufacturers 2013-2018
• 5.5 Market Concentration

6 Regions Market Performance for Manufacturers

• 6.1 China Market Performance for Manufacturers
  • 6.1.1 China Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.1.2 China Chronic Idiopathic Constipation (CIC) Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.1.3 China Chronic Idiopathic Constipation (CIC) Drugs Price (USD/Unit) of Manufacturers 2013-2018
  • 6.1.4 China Chronic Idiopathic Constipation (CIC) Drugs Gross Margin of Manufacturers 2013-2018
  • 6.1.5 Market Concentration
• 6.2 Japan Market Performance for Manufacturers
  • 6.2.1 Japan Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.2.2 Japan Chronic Idiopathic Constipation (CIC) Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.2.3 Japan Chronic Idiopathic Constipation (CIC) Drugs Price (USD/Unit) of Manufacturers 2013-2018
  • 6.2.4 Japan Chronic Idiopathic Constipation (CIC) Drugs Gross Margin of Manufacturers 2013-2018
  • 6.2.5 Market Concentration
• 6.3 South Korea Market Performance for Manufacturers
  • 6.3.1 South Korea Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.3.2 South Korea Chronic Idiopathic Constipation (CIC) Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.3.3 South Korea Chronic Idiopathic Constipation (CIC) Drugs Price (USD/Unit) of Manufacturers 2013-2018
  • 6.3.4 South Korea Chronic Idiopathic Constipation (CIC) Drugs Gross Margin of Manufacturers 2013-2018
  • 6.3.5 Market Concentration
• 6.4 Taiwan Market Performance for Manufacturers
  • 6.4.1 Taiwan Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.4.2 Taiwan Chronic Idiopathic Constipation (CIC) Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.4.3 Taiwan Chronic Idiopathic Constipation (CIC) Drugs Price (USD/Unit) of Manufacturers 2013-2018
  • 6.4.4 Taiwan Chronic Idiopathic Constipation (CIC) Drugs Gross Margin of Manufacturers 2013-2018
  • 6.4.5 Market Concentration
• 6.5 India Market Performance for Manufacturers
  • 6.5.1 India Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.5.2 India Chronic Idiopathic Constipation (CIC) Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.5.3 India Chronic Idiopathic Constipation (CIC) Drugs Price (USD/Unit) of Manufacturers 2013-2018
  • 6.5.4 India Chronic Idiopathic Constipation (CIC) Drugs Gross Margin of Manufacturers 2013-2018
  • 6.5.5 Market Concentration
• 6.6 Southeast Asia Market Performance for Manufacturers
  • 6.6.1 Southeast Asia Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.6.2 Southeast Asia Chronic Idiopathic Constipation (CIC) Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.6.3 Southeast Asia Chronic Idiopathic Constipation (CIC) Drugs Price (USD/Unit) of Manufacturers 2013-2018
  • 6.6.4 Southeast Asia Chronic Idiopathic Constipation (CIC) Drugs Gross Margin of Manufacturers 2013-2018
  • 6.6.5 Market Concentration
• 6.7 Australia Market Performance for Manufacturers
  • 6.7.1 Australia Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.7.2 Australia Chronic Idiopathic Constipation (CIC) Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.7.3 Australia Chronic Idiopathic Constipation (CIC) Drugs Price (USD/Unit) of Manufacturers 2013-2018
  • 6.7.4 Australia Chronic Idiopathic Constipation (CIC) Drugs Gross Margin of Manufacturers 2013-2018
  • 6.7.5 Market Concentration
• 6.8 Market Performance for Manufacturers
  • 6.8.1 Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.8.2 Chronic Idiopathic Constipation (CIC) Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.8.3 Chronic Idiopathic Constipation (CIC) Drugs Price (USD/Unit) of Manufacturers 2013-2018
  • 6.8.4 Chronic Idiopathic Constipation (CIC) Drugs Gross Margin of Manufacturers 2013-2018
  • 6.8.5 Market Concentration

7 Asia-Pacific Chronic Idiopathic Constipation (CIC) Drugs Market Performance (Sales Point)

• 7.1 Asia-Pacific Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units) and Market Share by Regions 2013-2018
• 7.2 Asia-Pacific Chronic Idiopathic Constipation (CIC) Drugs Revenue (M USD) and Market Share by Regions 2013-2018
• 7.3 Asia-Pacific Chronic Idiopathic Constipation (CIC) Drugs Price (USD/Unit) by Regions 2013-2018
• 7.4 Asia-Pacific Chronic Idiopathic Constipation (CIC) Drugs Gross Margin by Regions 2013-2018

8 Development Trend for Regions (Sales Point)

• 8.1 Asia-Pacific Chronic Idiopathic Constipation (CIC) Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.2 China Chronic Idiopathic Constipation (CIC) Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.3 Japan Chronic Idiopathic Constipation (CIC) Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.4 South Korea Chronic Idiopathic Constipation (CIC) Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.5 Taiwan Chronic Idiopathic Constipation (CIC) Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.6 India Chronic Idiopathic Constipation (CIC) Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.7 Southeast Asia Chronic Idiopathic Constipation (CIC) Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.8 Australia Chronic Idiopathic Constipation (CIC) Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.8 Australia Chronic Idiopathic Constipation (CIC) Drugs Sales and Growth, Sales Value and Growth Rate2013-2018

9 Upstream Source, Technology and Cost

• 9.1 Upstream Source
• 9.2 Technology
• 9.3 Cost

10 Channel Analysis

• 10.1 Market Channel
• 10.2 Distributors

11 Consumer Analysis

• 11.1 Hospitals & Clinics Industry
• 11.2 Ambulatory Surgical Centres Industry
• 11.3 Long Term Care Centres Industry

12 Market Forecast 2019-2024

• 12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2019-2024
  • 12.1.1 Asia-Pacific Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Revenue (M USD) and Market Share by Regions 2019-2024
  • 12.1.2 Asia-Pacific Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units) and Growth Rate 2019-2024
  • 12.1.3 China Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.4 Japan Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.5 South Korea Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.6 Taiwan Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.7 India Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.8 Southeast Asia Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.9 Australia Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.10 Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
• 12.3 Sales (K Units), Revenue (M USD) by Types 2019-2024
  • 12.3.1 Overall Market Performance
  • 12.3.2 Lubiprostone Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.3.3 Linaclotide Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.3.4 Others Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
• 12.4 Sales by Application 2019-2024
  • 12.4.1 Overall Market Performance
  • 12.4.2 Hospitals & Clinics Sales and and Growth Rate 2019-2024
  • 12.4.3 Ambulatory Surgical Centres Sales and and Growth Rate 2019-2024
  • 12.4.4 Long Term Care Centres Sales and and Growth Rate 2019-2024
  • 12.4.5 Others Sales and and Growth Rate 2019-2024
• 12.5 Price (USD/Unit) and Gross Profit
  • 12.5.1 Asia-Pacific Chronic Idiopathic Constipation (CIC) Drugs Price (USD/Unit) Trend 2019-2024
  • 12.5.2 Asia-Pacific Chronic Idiopathic Constipation (CIC) Drugs Gross Profit Trend 2019-2024

13 Conclusion